##common.pageHeaderLogo.altText##

Technical comment

Vol. 151 No. 0102 (2021)

Comment on: Haubitz et al. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study

Cite this as:
Swiss Med Wkly. 2021;151:w20310
Published
04.01.2021

References

  1. Haubitz S, Bartlomé N, Bucheli Laffer E, Spelters C, Fankhauser H, Fux CA. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study. Swiss Med Wkly. 2020;150:w20173. doi:.https://doi.org/10.4414/smw.2020.20173
  2. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(4):452–60. doi:.https://doi.org/10.1017/ice.2014.88
  3. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(Suppl 6):21–7. doi:.https://doi.org/10.1111/1469-0691.12046
  4. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al.; ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73. doi:.https://doi.org/10.1016/S0140-6736(10)61266-4
  5. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012;46(5):397–400. doi:.https://doi.org/10.1097/MCG.0b013e3182431d78
  6. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3573–7. doi:.https://doi.org/10.3748/wjg.v16.i28.3573
  7. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189–93. doi:.https://doi.org/10.1016/S0140-6736(00)03592-3
  8. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591–7. doi:.https://doi.org/10.1086/430315
  9. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42(6):758–64. doi:.https://doi.org/10.1086/501126
  10. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40(1):1–15. doi:.https://doi.org/10.1016/S0195-6701(98)90019-6
  11. Hoshika K. [Pseudomembranous colitis (Clostridium difficile infection)]. Ryoikibetsu Shokogun Shirizu. 1999;(23 Pt 1):24–6. Article in Japanese.
  12. Thompson I, Hanrahan M. P29.11 Enhanced surveillance of Clostridium difficile infection. J Hosp Infect. 2010;76:S82. doi:.https://doi.org/10.1016/S0195-6701(10)60273-3